The Rise of Vertically Integrated Telehealth

The healthcare landscape is undergoing one of its most significant structural shifts in decades. As telehealth, compounding pharmaceuticals, and direct‑to‑consumer (DTC) care converge, vertically integrated platforms are emerging as the new power centers of patient engagement and revenue capture. Earth Science Tech, Inc. - ETST (OTC: ETST) is one of the small‑cap players quietly—but decisively—positioning itself at the forefront of this transformation.

A Market Tailwind: Compounding & Telehealth Enter a High‑Growth Cycle

The U.S. compounding pharmacy sector is entering a period of accelerated expansion, driven by personalized medicine, chronic‑care demand, and updated regulatory standards that have increased investor confidence. Analysts project rapid growth between 2026 and 2030 as innovation in formulation, automation, and 3D‑printed dosage forms reshape the category .

Simultaneously, vertically integrated telehealth platforms are dismantling the traditional pharmaceutical value chain. Companies that combine prescriber networks with in‑house fulfillment—mirroring the model of Hims & Hers, Ro, and Thirty Madison—are capturing margins historically unavailable to retail pharmacies, with some reporting gross margins near 79% .

This is the environment in which ETST is scaling.

Watch the Full Interview below, with host Carmel Fisher and CEO of Earth Science Tech, Giorgio Saumat:

ETST’s Strategic Advantage: Full‑Stack Integration

CEO Giorgio Saumat describes ETST as a strategic holding company with core assets in compounding pharmaceuticals and online telehealth—an architecture that mirrors the most successful DTC healthcare disruptors.

With subsidiaries including Peaks Curative, Mister Meds, and RxCompoundStore.com, ETST has built a vertically integrated ecosystem from patient intake to prescription fulfillment. The recent nationwide launch of MyOnlineConsultation.com completes this stack, synchronizing prescriber networks with ETST’s compounding operations and generating cash‑flow‑positive performance even in beta .

Financial Discipline: A Rare Strength in the OTC Markets

In an OTC landscape where dilution is common, ETST stands out:

• Cash‑flow positive

• Positive EPS

• Minimal debt

• No capital raises in three years

This level of balance‑sheet strength is uncommon among microcaps and positions the company favorably for a potential uplist.

Looking Ahead: Scaling Into a Consolidating Market

With the compounding pharmacy market projected to reach USD 22.56B by 2026 and expand at a 13.53% CAGR through 2035 , ETST’s timing is strategic.

As the industry consolidates and telehealth platforms seek integrated fulfillment partners, ETST’s nimble structure and diversified revenue streams may offer meaningful upside.

Sources:

1. Future Market Insights – USA Compounding Pharmacies Market (2026–2036)

2. Mordor Intelligence – Compounding Pharmacy Market Size & Forecast (2026–2031)

3. U.S. Compounding Pharmacy Market Forecast (2026–2035)

4. Coherent Market Insights – Global Compounding Pharmacies Market (2026–2033)

5. Business Research Insights – Global Compounding Pharmacy Market (2026–2035)https://earthsciencetech.com/management/